CDKI-73 NEW
| Price | $146 | $308 | $443 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-10-26 |
Product Details
| Product Name: CDKI-73 | CAS No.: 1421693-22-2 |
| Purity: 98.11% | Supply Ability: 10g |
| Release date: 2025/10/26 |
Product Introduction
Bioactivity
| Name | CDKI-73 |
| Description | CDKI-73 is a potent CDK9 inhibitor (Ki: 4 nM). It shows selective toxicity to CLL cells(LD50=80 nM) versus normal B cell and normal CD34+ cell(LD50>20 uM).The inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin. |
| In vitro | CDKI-73, one of the most potent CDK9 inhibitors, against a panel of AML cell lines and samples derived from 97 patients.?CDKI-73 induced cancer cells undergoing apoptosis through transcriptional downregulation of anti-apoptotic proteins Bcl-2, Mcl-1 and XIAP by majorly targeting CDK9[3]. |
| In vivo | CDKI-73 exhibited a favorable pharmacokinetic profile with oral bioavailability of F = 56% following a single intravenous bolus dose at 2 mg/kg and an oral dose at 10 mg/kg in mice [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 52 mg/mL (131.83 mM), Sonication is recommended. |
| Keywords | toxicity | myeloid | LS-007 | LS007 | LS 007 | low | leukemia | Inhibitor | inhibit | endosome | Cyclin dependent kinase | CLL | CDKI-73 | CDKI73 | CDKI 73 | CDK9 | CDK7 | CDK6 | CDK4 | CDK2 | CDK1 | CDK | Apoptosis | AML | Acute |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Flubendazole | Cysteamine hydrochloride | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | L-Glutamic acid | Tributyrin | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Inhibitor Library | NO PAINS Compound Library | Orally Active Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Cell Cycle Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1520.00/25mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-08-21 | |
| $0.00/1kg |
VIP2Y
|
Chongqing Zhihe Biopharmaceutical Co., Ltd.
|
2023-12-18 | |
| $0.00/5kg |
VIP2Y
|
Anhuyan (Hainan) Biotechnology Co., LTD
|
2025-06-12 | |
| $146.00/1mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-10-27 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY